Researchers identified newly reimbursed medicines and their six-month costs at the time of inclusion from Finland’s national register of reimbursed medicine purchases. They used statistical averages and distributions to describe the medicines and their initial costs. A linear regression model examined associations between initial costs and medicine characteristics. The analysis found that initial costs for medicines with orphan designation were 12.2 times higher than for other medicines (P < 0.001).

Almost one-third of the 193 medicines were cancer medicines, while 15% were described as first-of-kind medicines. The abstract also reports that the number of products entering the reimbursement system with limited evidence of benefits increased over the study period. This increase was an observed feature of reimbursement decisions; the available evidence does not establish that products with limited evidence were responsible for rising costs.

The findings are limited to the medicines included in the Finnish reimbursement system during 2011–2021 and to costs measured at the time of inclusion. The register-based design describes reimbursement patterns and statistical associations, but it does not determine whether the observed differences reflect clinical benefits, patient outcomes, budget effects or other factors. The available abstract does not report detailed adjustments for confounding, uncertainty around the cost estimates, a control group or a complete account of study limitations. It is also an abstract-level summary, and the publisher notes that the accessible research version remains subject to further edits before replacement by the final version of record.

Subject of Research: Trends in the initial costs and characteristics of new reimbursed outpatient medicines in Finland, 2011–2021

Article Title: A nationwide register study of new outpatient medicines: trends in initial costs and medicine selection in Finland, 2011–2021

Article References: Kaustiala, K., Rättö, H., Sarnola, K., Kurko, T., Wagner, A. K., & Koskinen, H. (2026). A nationwide register study of new outpatient medicines: trends in initial costs and medicine selection in Finland, 2011–2021. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15725-2

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15725-2

Keywords: Finland, outpatient medicines, drug reimbursement, health expenditures, orphan medicines, cancer medicines, biologic medicines, register study, initial treatment costs, nationwide, register, outpatient

The study, led by Vincent Mougin of the Karolinska Institutet together with collaborators including researchers at the Institute for Health Metrics and Evaluation, harnessed the extraordinary statistical infrastructure of the Swedish state. By linking the Total Population Register, the National Patient Register, the Cause of Death Register and the LISA labour market database, the team assembled a cohort of nearly 6.85 million unique individuals diagnosed between 2001 and 2023, contributing more than 196 million person-years of observation. That scale, and the near-complete population coverage of Scandinavian registers, allowed something no previous study had achieved: a harmonised, like-for-like comparison of income-related survival gaps across the entire spectrum of non-communicable disease.

The technical approach was as important as the scale. Rather than comparing raw survival rates — which would be hopelessly confounded, since low-income Swedes tend to be older, and differ in sex distribution and era of diagnosis — the researchers used flexible parametric survival models with regression standardisation. Restricted cubic splines captured the shape of the baseline hazard over time without forcing the data into proportional hazards assumptions, and standardisation produced marginal survival curves: estimates of what survival would look like if everyone in a cohort shared the same income level while keeping their actual age, sex and diagnosis year. Income itself was defined carefully, using five-year lagged, consumption-equivalised household disposable income ranked into quartiles within sex and birth-year strata, a technique designed to strip out short-term income shocks caused by illness itself.

The headline finding is stark in its uniformity. After standardisation, individuals in the bottom income quartile had lower ten-year survival than those in the top quartile for all 100 disease categories, and the confidence interval for the difference excluded zero in every case. For 37 conditions, the absolute gap exceeded ten percentage points. The largest per-person disparities clustered around smoking- and alcohol-related diseases: ten-year survival for other pharynx cancer was 34.2 percent among the poorest versus 58.2 percent among the richest — a 24-point chasm in a country where chemotherapy, surgery and radiotherapy are free at the point of use. Larynx cancer, lip and oral cavity cancer, chronic obstructive pulmonary disease, endocarditis and aortic aneurysm all showed gaps of more than 14 percentage points.

One especially striking pattern emerged in diseases with intermediate prognoses. For conditions where overall ten-year survival hovered between roughly 40 and 60 percent — a group dominated by cardiovascular disease — income acted almost as a switch. Ten years after an ischaemic heart disease diagnosis, the researchers note, a Swede in the top income quartile is more likely to be alive than dead, while someone in the bottom quartile is more likely to be dead than alive. The same grim arithmetic holds for hypertensive heart disease, ischaemic and haemorrhagic stroke, aortic aneurysm, prostate cancer and several others. The authors suggest this may reflect a mix of statistical floor and ceiling effects — survival differences are mechanically compressed where nearly everyone lives or nearly everyone dies — alongside the fact that these intermediate conditions are precisely where treatment quality, adherence and risk-factor management tip outcomes.

To express the gaps in a clinically intuitive metric, the team calculated ten-year restricted mean survival time, effectively the average number of years lived within a decade of diagnosis. Low-income patients with other pharynx cancer lost 1.90 years compared with high-income patients, larynx cancer patients 1.46 years, and COPD patients just over a year. But when the researchers scaled these per-person differences up to the population level, the picture inverted. Rare head and neck cancers, despite their enormous individual gaps, contributed relatively little to the national total because so few people are diagnosed. Instead, the greatest absolute burden came from humdrum, highly prevalent conditions: hypertension alone accounted for roughly 352,000 person-years of survival lost among low-income patients, with atrial fibrillation, stroke, heart failure and urinary tract infections close behind. In total, about 6.2 million person-years of survival were lost within ten years of diagnosis — the difference between what low- and middle-income patients actually experienced and a counterfactual in which they had enjoyed high-income survival trajectories.

Perhaps the most methodologically sophisticated part of the study tackled a deceptively simple question: are these gaps just the familiar income gradient in life expectancy showing through, or does income specifically change what happens after you are diagnosed? The researchers matched each diagnosed patient to five disease-free controls sharing the same birth year, sex and income quartile, then compared survival loss relative to those controls across income groups. For 73 of the 100 disease categories, the poorest patients lost significantly more survival time to their disease than the richest — a difference that persisted after netting out background mortality. This extends a logic familiar from deprivation-stratified relative survival analyses in cancer epidemiology, but applies it across cardiovascular, respiratory, neurological and mental health conditions, suggesting the pattern is not a cancer quirk but a general feature of illness in an unequal society.

Why does income still matter so much in a welfare state? The observational design cannot pin down mechanisms, but the authors sketch two non-exclusive pathways. First, lower income may worsen the course of disease after onset — through later presentation, differences in treatment, adherence to medication, management of comorbidities, and the practical costs of being ill, such as prescription charges, travel and lost earnings. Second, low-income patients may simply enter the register later, at a more advanced stage of disease, since cohort entry here marks first recorded specialist care rather than true disease onset. The breadth of the findings, spanning fast-moving cancers where early detection is everything and slow chronic diseases where long-term management dominates, suggests no single mechanism suffices. Upstream forces compound the problem: smoking and alcohol harm concentrate among the poor, financial insecurity feeds chronic stress, cheaper processed diets and low-control work add cardiovascular risk, and disadvantages accumulate within the same people across a lifetime.

The authors caution that their estimates are probably conservative. Older people living on modest pensions may be misclassified as low-income despite secure circumstances, diluting the measured association, and Sweden’s comparatively low inequality and strong safety nets likely mean the gaps would be wider in countries with higher out-of-pocket costs. Still, income inequality in Sweden has risen faster than in most OECD countries in recent decades, and the life expectancy gap between rich and poor has widened in parallel. For policymakers, the study offers a triage map: intervening on prevalent cardiovascular conditions such as hypertension and ischaemic heart disease would deliver the largest absolute reductions in survival inequality, while focused prevention and early detection for smoking- and alcohol-related cancers — including HPV-driven pharyngeal tumours — would benefit each affected person most. More broadly, the findings are a reminder that universal coverage removes the price tag on a hospital bed but not the many other ways that money buys health.

Subject of Research: Income-related survival disparities across 100 disease categories in Sweden

Article Title: Income-related differences in survival across disease categories in Sweden: a retrospective population-based register study

Article References: Mougin, V., Gray, A., Naghavi, M., Allebeck, P., Kinge, J. M., Wool, E. E., Weaver, N. D., Murray, C. J., & Agardh, E. E. (2026). Income-related differences in survival across disease categories in Sweden: a retrospective population-based register study. The Lancet Regional Health – Europe, 71, Article 101896. https://doi.org/10.1016/j.lanepe.2026.101896

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101896

Keywords: health inequality, survival analysis, Sweden, income, non-communicable diseases, cardiovascular disease, cancer, COPD, universal healthcare, register study, life expectancy, epidemiology

The research team, led by Timo Purmonen of Oriola together with colleagues from Takeda Oy, Kuopio University Hospital and Terveystalo, conducted a nationwide retrospective matched cohort study using Finnish administrative register data. They identified all individuals of any age who received a new ADHD diagnosis or related record during 2015 to 2020, and matched each of them with up to four controls of the same age, sex and region who had no recorded ADHD. Every participant was then followed from their index date until death, emigration, or the end of 2021, yielding an average follow-up of 3.5 years. The final study population comprised 64,752 individuals with newly identified ADHD and 256,270 matched controls, a dataset of extraordinary statistical power.

What makes this study technically distinctive is its foundation in linked national registers rather than self-reported surveys or clinical samples. Finnish law permits the secondary use of pseudonymised administrative data under the Act on the Secondary Use of Health and Social Data, and the researchers obtained statutory data permits from the Finnish Social and Health Data Permit Authority Findata, Statistics Finland, the Finnish National Agency for Education and the Legal Register Centre. This allowed them to track academic performance, educational attainment, employment status, social benefit payments, marital status, criminal convictions, healthcare resource utilization and both direct and indirect costs across the entire population, without the selection bias and attrition that plague conventional cohort studies. Because the design was observational, the authors emphasize that it was not built to establish whether diagnosis or treatment causes the observed differences.

The educational findings are sobering. Individuals with newly identified ADHD showed consistently poorer academic performance and lower educational attainment than their matched peers. This matters because educational attainment is one of the strongest predictors of lifetime earnings, health and social stability, and a deficit established early can compound across decades. The register approach captured these outcomes across all ages, meaning the study could document not just how children with ADHD fare in school, but how adults who were identified later in life had already diverged from the population baseline in their completed qualifications.

Employment outcomes revealed some of the widest gaps in the entire study. Long-term unemployment was substantially more common among individuals with ADHD than among controls: 15.3 percent of females with ADHD versus 8.2 percent of female controls, and 20.5 percent of males with ADHD versus 10.7 percent of male controls. In other words, men with newly identified ADHD were nearly twice as likely to be out of work long term as their peers, and women were similarly disadvantaged. These figures translate directly into lost productivity and increased reliance on social transfers, which the cost analysis quantified in euros.

Perhaps the most striking single statistic concerns the criminal justice system. Imprisonment was recorded far more frequently among individuals with ADHD, particularly males, at 5.1 percent compared with 1.1 percent in matched controls, a more than fourfold difference. While the study was not designed to explain this association, it is consistent with a large body of international research linking impulsivity, substance use and socioeconomic disadvantage in ADHD to elevated rates of criminal convictions. The finding underscores that the burden of the disorder is borne not only by individuals and health systems but also by the justice sector and, ultimately, by society at large.

Healthcare utilization told a similarly consistent story. Across every age group, individuals with ADHD used more healthcare resources than controls, with the largest differences observed in psychiatric secondary care. Among adults, annual direct healthcare costs reached €4,290 for females with ADHD compared with €1,795 for female controls, and €3,641 for males with ADHD compared with just €1,082 for male controls. That means adult men with ADHD generated more than three times the direct healthcare costs of their matched peers, and adult women roughly two and a half times. The elevated psychiatric care burden suggests that comorbid mental health conditions, which are common in ADHD, drive much of this excess utilization.

The economic analysis extended beyond healthcare to income and welfare. Annual earned income was €7,031 lower among females with ADHD and €10,745 lower among males with ADHD than among matched controls. At the same time, annual social transfer payments were €2,806 higher for females and €2,695 higher for males with the disorder. Taken together, these figures describe a double burden: individuals with ADHD earn substantially less while drawing more in public support, and the health system spends far more on their care. Multiplied across tens of thousands of affected individuals, the aggregate societal cost is enormous, even before accounting for the intangible costs of reduced wellbeing and opportunity.

The study’s scale and rigor give its conclusions unusual weight, but the authors are careful about interpretation. Because the cohort consisted of people with newly identified ADHD during a period when diagnostic rates in Finland were rising sharply, the sample likely includes many adults diagnosed late in life, a group whose socioeconomic difficulties may have contributed to their eventually coming to clinical attention. The observational design cannot separate the effects of the disorder itself from those of comorbidities, treatment access or social circumstances. The study was also funded by Takeda Oy, a pharmaceutical manufacturer, though the sponsor reports having had no role in study design, data analysis or interpretation, and the authors declare no competing interests. These caveats do not diminish the descriptive power of the data; they simply frame what the numbers can and cannot tell us.

What the numbers do tell us is unambiguous: the burden of ADHD extends far beyond healthcare into education, labor markets, welfare systems and the criminal justice system. For policymakers, the study provides a national-scale evidence base for investing in earlier identification, better access to treatment and supported transitions from school to work. For clinicians, it is a reminder that an ADHD diagnosis carries implications that reach into every domain of a patient’s life. And for the hundreds of thousands of people living with the disorder and their families, it offers validation that the challenges they face are real, measurable and shared by a substantial fraction of the population. As diagnostic rates continue to climb across the developed world, studies of this kind will be essential for deciding where scarce public resources can do the most good.

Subject of Research: The educational, socioeconomic, healthcare and societal burden of newly identified ADHD in Finland

Article Title: Burden of attention deficit hyperactivity disorder (ADHD) on people and society in Finland – a nationwide register study in 2015–2021

Article References: Purmonen, T., Iso-Mustajärvi, I., Kallio, A., Jukka, J., Puustjärvi, A., & Leppämäki, S. (2026). Burden of attention deficit hyperactivity disorder (ADHD) on people and society in Finland – a nationwide register study in 2015–2021. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08729-z

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08729-z

Keywords: ADHD, Finland, register study, disease burden, healthcare costs, unemployment, education, criminal convictions, social benefits, cohort study, psychiatry, socioeconomic outcomes

The research, published in the International Journal of Obesity, exploits one of the distinctive strengths of the Nordic research infrastructure. In Finland, comprehensive national registers record prescription drug purchases, healthcare utilization, education, income, employment status, family structure and place of residence for virtually the entire population. By linking these registers at the individual level, researchers can assemble an exceptionally complete picture of medication use across society, free from the recall bias, volunteer bias and loss to follow-up that plague conventional surveys. This makes register studies of this kind uniquely suited to detecting systematic patterns in who accesses treatment and who is left behind.

The scale of the analyzed population matters for the credibility of the findings. With more than a quarter of a million Finnish adults in the study cohort, even relatively small differences in medication uptake between social groups become statistically detectable, and the results are far less likely to be distorted by random variation. Small clinical studies, which typically follow a few hundred patients at specialized obesity clinics, capture only the narrow slice of people who reach tertiary care. A register study, by contrast, observes the full pipeline, from primary care prescriptions through pharmacy dispensing records, and therefore reflects everyday clinical practice rather than the highly selected environment of academic weight-management centers.

Why should the distribution of anti-obesity medication be socially patterned at all? In principle, obesity is not distributed evenly across society in the first place. Decades of epidemiological research, particularly in high-income countries, have consistently shown that obesity prevalence is inversely associated with socioeconomic position: people with lower levels of education and income carry a higher burden of obesity in many populations. If treatment followed need, one would therefore expect anti-obesity medications to be prescribed at least as often, and possibly more often, to people from disadvantaged backgrounds. Whether that is actually the case is the empirical question at the heart of the Finnish register study.

The answer is far from guaranteed, because multiple forces pull access in different directions. On one side sit barriers that tend to concentrate among socioeconomically disadvantaged groups: out-of-pocket medication costs, the ability to navigate healthcare systems, geographic distance from providers who prescribe these drugs, and the time and flexibility required for the frequent follow-up appointments that anti-obesity pharmacotherapy typically demands. On the other side sit factors that may favor advantaged groups or, in some contexts, disadvantage them differently, including physician prescribing preferences, awareness of and demand for newer therapies, and insurance or reimbursement structures that determine how much of the medication price each patient must shoulder.

Anti-obesity pharmacotherapy is also a moving target, and this temporal dimension shapes any register analysis. Older agents, such as orlistat, which acts by inhibiting intestinal fat absorption, and older noradrenergic appetite suppressants, have been joined in recent years by glucagon-like peptide-1 receptor agonists originally developed for type 2 diabetes and subsequently approved for chronic weight management. These newer agents have demonstrated substantially greater average weight loss in randomized trials, but they are also expensive, administered by weekly injection, and often subject to reimbursement restrictions and supply shortages. The social profile of who uses anti-obesity medications is therefore not static; it evolves as the drug landscape, the regulatory environment and public attention to obesity treatment change.

Register data allow researchers to trace these patterns across the entire adult population, stratifying medication use by sex, age, education, income, employment and family circumstances. This multidimensional approach is important because socioeconomic position is not a single variable. Education captures early-life and cognitive resources, income captures current material means, and employment captures attachment to institutions that shape healthcare access. Different dimensions can point in different directions: for instance, medication use might rise with income while showing a different gradient with age or family status. Only a sufficiently large and richly linked dataset can disentangle these overlapping gradients, which is precisely the analytical opportunity afforded by the Finnish registers.

Finland offers a particularly informative setting for this kind of inquiry. Like its Nordic neighbors, it provides tax-funded healthcare to all residents, which softens but does not eliminate the role of purchasing power in treatment access. Prescription medications in Finland are subject to a tiered reimbursement system administered through the national health insurance scheme, and anti-obesity drugs have historically faced strict limits on reimbursement, leaving many patients to pay substantial costs out of pocket. Primary health centers deliver most routine care, while referral pathways govern access to specialized obesity treatment. How these institutional arrangements translate into equitable or inequitable access is exactly the sort of question that register linkage can address with a precision unattainable in most other countries.

The stakes of the question extend well beyond Finland. Health systems worldwide are confronting an unprecedented surge in demand for anti-obesity medications, driven both by rising obesity prevalence and by the demonstrated efficacy of newer agents. Supply constraints, insurance coverage debates and clinical guideline decisions all hinge on assumptions about who benefits from and who deserves access to these therapies. If real-world uptake is systematically skewed by education, income or demography, then the newest and most effective obesity treatments risk widening existing health inequalities rather than narrowing them, echoing patterns previously documented for bariatric surgery, where uptake has often been concentrated among groups that are urban, insured and socioeconomically advantaged despite obesity being more prevalent elsewhere.

For researchers, the Finnish register study of 282,307 adults provides a template for monitoring this emerging therapeutic landscape systematically. For clinicians and policymakers, it underscores that the effectiveness of anti-obesity medications in populations depends not only on their performance in randomized trials but on whether the people who need them most actually receive them. As new agents enter the market and reimbursement policies are revised, continued surveillance of sociodemographic and socioeconomic gradients in medication use will be essential to ensure that the pharmacological revolution in obesity treatment reaches all segments of society rather than only those already best positioned to seize it.

Subject of Research: Sociodemographic and socioeconomic differences in anti-obesity medication use among Finnish adults

Article Title: Sociodemographic and socioeconomic differences in the use of anti-obesity medications: a register study among 282,307 Finnish adults

Article References: Valkonen, J., Svärd, A. C., Roos, E., Joki, A., Kouvonen, A., & Lallukka, T. (2026). Sociodemographic and socioeconomic differences in the use of anti-obesity medications: a register study among 282,307 Finnish adults. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02213-0

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02213-0

Keywords: anti-obesity medications, socioeconomic differences, register study, Finland, obesity treatment, health inequality, pharmacotherapy, prescription drugs, obesity epidemiology, healthcare access, Sociodemographic, socioeconomic